Sophie Pakianather
Overview
Explore the profile of Sophie Pakianather including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Descamps D, Assoumou L, Chaix M, Chaillon A, Pakianather S, de Rougemont A, et al.
J Antimicrob Chemother
. 2013 Jun;
68(11):2626-31.
PMID: 23798669
Objectives: As recommended by the French ANRS programme for the surveillance of HIV-1 resistance, we estimated the prevalence of transmitted drug resistance-associated mutations (RAMs) in antiretroviral-naive, chronically HIV-1-infected patients. Methods:...
2.
Assoumou L, Descamps D, Yerly S, Dos Santos G, Marcelin A, Delaugerre C, et al.
J Antimicrob Chemother
. 2013 Feb;
68(6):1400-5.
PMID: 23404192
Background: Surveillance of HIV-1 drug resistance in treated patients with plasma viral load (VL) >50 copies/mL. Methods: The protease and reverse transcriptase (RT) genes were systematically sequenced in samples from...
3.
Lambert-Niclot S, Flandre P, Valantin M, Soulie C, Fourati S, Wirden M, et al.
PLoS One
. 2012 Aug;
7(7):e41390.
PMID: 22848481
Background: A higher proportion of intermittent viremia (to have a HIV-1 RNA viral load>50 copies/mL not confirmed) was reported in the boosted protease inhibitor monotherapy arm in some studies including...
4.
Gasnault J, Costagliola D, Hendel-Chavez H, Dulioust A, Pakianather S, Mazet A, et al.
PLoS One
. 2011 Jul;
6(6):e20967.
PMID: 21738597
Background: Progressive multifocal leukoencephalopathy (PML), a rare devastating demyelinating disease caused by the polyomavirus JC (JCV), occurs in severely immunocompromised patients, most of whom have advanced-stage HIV infection. Despite combination...
5.
Descamps D, Chaix M, Montes B, Pakianather S, Charpentier C, Storto A, et al.
J Antimicrob Chemother
. 2010 Oct;
65(12):2620-7.
PMID: 20965891
Objectives: To estimate the prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-1-infected patients in France. Methods: Resistance mutations were sought in samples from 530...
6.
Katlama C, Valantin M, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard P, et al.
AIDS
. 2010 Aug;
24(15):2365-74.
PMID: 20802297
Background: Darunavir/ritonavir (darunavir/r) maintenance strategy, in patients with suppressed HIV RNA viremia, is a potential long-term strategy to avoid nucleoside analogue toxicities and to reduce costs. Methods: MONOtherapy Inhibitor protease...
7.
Lambert-Niclot S, Peytavin G, Duvivier C, Poirot C, Algarte-Genin M, Pakianather S, et al.
Antimicrob Agents Chemother
. 2010 Aug;
54(11):4910-3.
PMID: 20713677
HIV-1 RNA level and darunavir concentration in the genital tract were measured in 45 men receiving darunavir-ritonavir mono- or tritherapy. At week 48, a low frequency (3/45) of HIV-1 RNA...